Pellagra Treatment Market Size
The global Pellagra Treatment market reached USD 56.26 million in 2025 and is expected to reach USD 96.60 million by 2033, growing at a CAGR of 6.8% during the forecast period from 2026 to 2033.
The market is experiencing gradual growth due to increasing awareness regarding nutritional deficiency disorders, rising cases of malnutrition in developing regions, and improved diagnosis of vitamin B3 deficiency-related diseases. Expanding healthcare infrastructure and government nutrition programs are also supporting the demand for pellagra treatment therapies.
Market growth is being driven by the increasing adoption of niacin and nicotinamide supplementation therapies, especially in regions with high nutritional deficiency prevalence across Asia, Africa, and Latin America. Oral vitamin B3 supplements continue to dominate the treatment segment due to their affordability, accessibility, and effectiveness. In addition, public health initiatives focused on food fortification and nutritional awareness are improving patient identification and treatment access. Regulatory support and expanding distribution networks through hospital pharmacies, retail pharmacies, and online channels are further enhancing market penetration.
Recent industry developments are strengthening market access and product availability. In 2025, Zydus received U.S. FDA approval for extended-release niacin tablets in multiple dosage strengths, supporting broader therapeutic availability in the United States market. Furthermore, increasing collaborations between pharmaceutical companies, NGOs, and healthcare agencies are improving access to nutritional therapies in underserved populations. Governments and international healthcare organizations are also investing in preventive nutrition programs and fortified food initiatives to reduce disease burden while ensuring sustained treatment demand.
The future outlook for the Pellagra Treatment market remains positive, supported by advancements in nutritional therapeutics, growing awareness of micronutrient deficiencies, and expanding healthcare access in emerging economies. Integration of digital health tools, remote patient monitoring, and personalized nutrition management is expected to improve treatment adherence and patient outcomes. In addition, increasing investments in rare disease management and orphan healthcare programs are likely to create new growth opportunities for manufacturers and healthcare providers over the coming years.
Pellagra Treatment Market Scope
| Metrics | Details |
| Market CAGR | High |
| Segments Covered | By Type, By Distribution Channel, and By Region |
| Report Insights Covered | Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights. |
| Fastest Growing Region | Asia Pacific |
| Largest Market Share | North America |
To Know More Insights - Download Sample
Pellagra Treatment Market Dynamics
The factors influencing the global pellagra treatment market are the increasing research and development and the increasing prevalence of pellagra.
The increasing research and development is expected to drive the market growth in the forecast period
Pellagra is a disease caused by a dietary deficiency in niacin (one of the B complex vitamins) or tryptophan (an amino acid). The triad of dermatitis, diarrhea, and dementia are the classic clinical features of pellagra, though most people do not have all three. Headache, irritability, poor concentration, apathy and confusion, vertigo, myoclonus, tremor, rigidity, weakness, dysphagia, seizures, and various psychiatric symptoms are all examples of neurologic abnormalities. Patients become disoriented, confused, and delirious as pellagra progresses, then stuporous and comatose, and finally die.
Pellagra can occur in people with Crohn's disease due to niacin deficiency caused by malabsorption and tryptophan wastage combined with increased 5-hydroxyindoleacetic acid excretion in the urine. Pellagra has been linked to infectious colitis and malabsorption caused by intestinal bacterial overgrowth. Niacin, also known as vitamin B3, is a generic name for two compounds: nicotinamide and nicotinic acid. It is required for carbohydrate, fat, protein, alcohol metabolism, drug and reactive oxygen species detoxification, cell signaling, and DNA repair. Niacin-rich foods include tuna fish, chicken, beef, peanuts, mushroom, avocado, and green peas, with recommended daily intakes of 14 mg. At the same time, HIV patients are expected to have higher niacin requirements. Moreover, the WHO recommends taking at least 300 mg nicotinamide in an oral divided daily dose for 3–4 weeks to treat pellagra. Niacin-induced flushing necessitates the use of nicotinamide. General malnutrition and cachexia may necessitate the use of additional dietary supplements.
Limitations associated with pellagra treatment are expected to hamper the market growth
Niacin is probably safe for most people when taken by mouth. Niacin can cause a flushing reaction, a common minor side effect. Side effects include burning, tingling, itching, redness of the face, arms, chest, and headaches. Starting with small doses of niacin and taking 325 mg of aspirin before each dose of niacin can help to reduce the flushing reaction. This reaction usually subsides as the body adjusts to the medication. Alcohol can exacerbate the flushing reaction. When taking niacin, one should stay away from large amounts of alcohol. Concerns have been raised about the risk of stroke in people who take niacin. According to one large study, people who took high doses of niacin had a two-fold higher risk of stroke than those who did not take niacin.
Pellagra Treatment Market Segment Analysis
Primary pellagra is expected to dominate the market growth
Diets low in niacin or tryptophan cause primary pellagra. Because tryptophan is converted to niacin in the body, a lack of it can result in a niacin deficiency. Primary pellagra is common in developing countries where corn (maize) is a major food source or aftermath of long-term disasters such as famine or war. Corn is high in niacin, but it is locked up in a bound form that can only be accessed with alkaline solutions, and corn proteins are low in tryptophan. Pellagra is still endemic in India, China, and parts of Africa.
Dietary and lifestyle changes and a niacin or nicotinamide supplement treat primary pellagra. Nicotinamide is another form of Vitamin B3 used to treat pellagra in its early stages. When a disease is detected early on, it is possible to recover completely within a few days of starting treatment. On the other hand, skin improvement may take some time (usually a few months). When pellagra is left untreated, it can lead to death in as little as 4-5 years.
Pellagra Treatment Market Geographical Share
North America region is expected to hold the largest market share in the global pellagra treatment market
The growing prevalence of pellagra and increasing research and development in this region is expected to drive the market growth.
Pellagra (a niacin deficiency disease) claimed more than 100,000 lives in the United States alone, affecting more than 3 million people. Pellagra reached epidemic proportions in the American South in the early 1900s. Pellagra infected over 3 million Americans during that time, resulting in over 100,000 deaths, but the epidemic ended after dietary niacin fortification. Hence, with pellagra's increasing prevalence, the demand for its treatment increased. And is expected to boost the market growth in North America region.
Key Developments
February 2026: Increasing awareness regarding vitamin B3 deficiency disorders accelerated early diagnosis and treatment adoption for pellagra, particularly in developing regions with high malnutrition prevalence.
January 2026: Rising government and public health initiatives promoting nutritional supplementation programs supported improved access to niacin-based therapies for pellagra management.
December 2025: Growing integration of fortified food products and dietary intervention strategies strengthened preventive approaches against pellagra and related nutritional deficiencies.
November 2025: Expansion of healthcare outreach programs in rural and underserved communities improved screening and treatment rates for pellagra patients.
October 2025: Increasing prevalence of chronic alcoholism, gastrointestinal disorders, and malabsorption conditions contributed to higher demand for effective pellagra treatment solutions.
September 2025: Advancements in nutritional therapeutics and oral vitamin supplementation formulations enhanced patient compliance and treatment outcomes in pellagra care.
August 2025: Rising focus on personalized nutrition and deficiency management supported the development of targeted vitamin replacement therapies for niacin deficiency disorders.
July 2025: Growing investments in clinical nutrition research and public health nutrition programs accelerated awareness campaigns and improved availability of pellagra treatment products globally.
Pellagra Treatment Market Companies and Competitive Landscape
With mergers, acquisitions, and product launches, the global pellagra treatment market is moderately competitive. Some of the key players in the market are DSM, Merck KGaA, Foodchem International Corporation, Jubilant Life Sciences Limited, Western Drugs Ltd., Lasons, Bazayan & Co, Resonance Specialties Limited, Veer-Chemie
Western Drugs Ltd.
Overview: Western Drugs Ltd. is a leading manufacturer of Niacin (Nicotinic Acid) and Niacinamide. The company was founded in 1989 and is headquartered in India.
Product Portfolio: Vitamin B3 Niacin (Nicotinic Acid) is a nutrient additive used in food, feed, and pharmaceutical/nutritional products. It is an essential B complex vitamin, also known as Vitamin B3, with various uses. It is available in powder and granular form.
